Sachin Gupta
Critical Care Medicine · Oakland, CANPI 1215163183
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Boehringer Ingelheim at 50.4% of the total. Reporting peaked in 2019 at $70,949 and has fallen 99.6% since, to $254 in 2025. Among critical care medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $501.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$43K
- Bayer$25K
- Insmed, Inc.$8K
- United Therapeutics Corporation$6K
- Actelion Pharmaceuticals US, Inc.$3K
- Merck$177
- plus $308 from 8 others
Across 7 payments — averaging $5023.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$35K
What the payments were for
- Consulting fees$30,93636%
- Speaking & faculty fees$38,12044%
- Travel & lodging$11,42213%
- Food & beverage$5,2546%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 57 | $43,188 |
| Bayer | 49 | $24,603 |
| Insmed, Inc. | 13 | $8,408 |
| United Therapeutics Corporation | 24 | $5,979 |
| Actelion Pharmaceuticals US, Inc. | 11 | $3,069 |
| Merck | 5 | $177 |
| Novartis | 5 | $94 |
| Accord Healthcare, Inc. | 1 | $57 |
| Avyxa Pharma, LLC | 1 | $54 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| GSK | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$85,732 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 14 | $315,013 |
| Ambrisentan | 23 | $65,550 |
| Sildenafil Citrate | 23 | $19,562 |
| Tadalafil | 17 | $2,370 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $412 |
| Spironolactone | 26 | $157 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Oakland
- Cedric Franklin RutlandRiverside$3.2M
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Stephen ChenMonterey Park$394K
- Bassam YaghmourOrange$376K
- Xuanha WhiteSan Diego$343K
- Ken YonedaSacramento$173K
- Praveen AkuthotaSan Diego$169K
- Ivan ChengSan Francisco$162K
- Brian ShermanOxnard$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.